Loading clinical trials...
Loading clinical trials...
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Conditions
Interventions
Iodine I-131
Placebo Administration
+1 more
Locations
11
United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
Hoag Memorial Hospital
Newport Beach, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
MedStar Georgetown University Hospital
Washington D.C., District of Columbia, United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Start Date
May 4, 2015
Primary Completion Date
July 17, 2020
Completion Date
December 31, 2023
Last Updated
July 26, 2024
NCT04693377
NCT04061980
NCT03914300
NCT02152995
NCT03449108
NCT01552434
Lead Sponsor
Academic and Community Cancer Research United
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions